Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 10/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451131 | 0.91 | NPC1 (0.52) | CXCR3PIK3CDPIK3R1ALDH1A1PIK3CG | |
| SCHEMBL450858 | 0.89 | SMN1; SMN2 (0.57) | CXCR3PDE10AMEN1ALDH1A1KMT2A | |
| SCHEMBL453737 | 0.88 | SMN1; SMN2 (0.58) | PIK3CDPIK3R1PDE10AMEN1ALDH1A1 | |
| SCHEMBL447902 | 0.88 | PTGS2 (0.49) | PIK3CDMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1553219 | 0.87 | CXCR3 (0.52) | CXCR3 | |
| SCHEMBL452172 | 0.85 | ALDH1A1 (0.61) | CXCR3PDE10AMEN1ALDH1A1KMT2A | |
| SCHEMBL1553362 | 0.85 | KCNH2 (0.44) | CXCR3PIK3CDPIK3R1ALDH1A1SMN1; SMN2 | |
| SCHEMBL450044 | 0.85 | MEN1 (0.47) | CXCR3PIK3CDMEN1ALDH1A1KMT2A | |
| SCHEMBL1484065 | 0.85 | CXCR3 (0.56) | CXCR3PDE10AMEN1ALDH1A1KMT2A | |
| SCHEMBL14317533 | 0.85 | CXCR3 (0.56) | CXCR3PDE10AMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110077256-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | GUICHERIT OIVIN M | 2011-03-31 | — | — | US | disclosed |
| US-20110077256-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | GUICHERIT OIVIN M | 2011-03-31 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-1516876-A1 | Mediators of hedgehog signalling pathways, compositions and uses related thereto | Curis, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1216234-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-6545005-B1 | Quinazolone derivatives | CURTIS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001019800-A9 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1216234-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | Curis, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019800-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | CXCR3 741/4885PIK3CD 1577/4885PIK3R1 811/4885 |
| US-20110077256-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | SHH, SMO, GLI1 | CXCR3 1281/4885PIK3CD 310/4885PIK3R1 274/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | CXCR3 741/4885PIK3CD 1577/4885PIK3R1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.